Skip to content

Homoeopathic Treatment for Skin Irritation Caused by Irritants Using Rhus Venenata and Its Effect on Daily Life

The Scope of Rhus Venenata in Management of Irritant Contact Dermatitis Considering Dermatological Life Quality Index - an Interventional Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104829
Enrollment
36
Registered
2026-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L249- Irritant contact dermatitis, unspecified cause

Interventions

Intervention1: Rhus Venenata: Rhus Venenata will be administered Based on the Study Subjects Suffering from irritant contact dermatitis orally for the duration of once in 15 days for 3 months and late

Sponsors

Dr Harsha Math
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Subjects of age group 20-50 years of age and both sexes 2) Subjects with clinical diagnosed cases based on dermatology life quality index who are more than 10 score 3) Subjects who are willing to take only homoeopathic medicine during treatment are included 4) Subjects satisfying the diagnostic criteria.

Exclusion criteria

Exclusion criteria: 1)Subjects are on hormonal treatment, pregnant and lactating women 2) Subjects with known cases of immunocompromised will not be taken for study 3) Subjects who are already taking any other medication for irritant contact dermatitis 4) Subjects with other systemic or congenital abnormalities 5) Subjects not able to fill the dermatology life quality index questionnaire

Design outcomes

Primary

MeasureTime frame
Recovered, No recurrence of the complaints and symptoms during study period. Improved if more then or equals to 50 percentage reduction in the severity of the DLQI questionnaire or no recurrence of symptoms during the study period Not improved. No reduction in the intensity of DLQI questionnaire by 25 percentage or recurrence of symptoms during the study periodTimepoint: The First 3 months, Follow up will be Taken For Every 15 Days. For The Next 3 Months Follow up will be Taken Once a Month and also as Per Need of the Case

Secondary

MeasureTime frame
NOT APPLICABLETimepoint: NOT APPLICABLE

Countries

India

Contacts

Public ContactDr Harsha Math

Bharatesh Homoeopathic Medical College Hospital

drcjdesai71@gmail.com9448824628

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026